News | September 23, 2013

Facility Recognized for Quality Controls in Platelet Function Analyzer Manufacturing

September 23, 2013 – Aggredyne Inc., has received ISO 13485 certification for its quality control program related to the manufacture of the AggreGuide family of platelet function analyzers.

The ISO 13485 certification covers the design, development, production, sales and service of the AggreGuide instrument and reagent cartridges. The certificate demonstrates that Aggredyne has successfully implemented a quality management system that conforms to the worldwide standard for medical device and diagnostic manufacturing.

The International Organization for Standardization (ISO) is the world's largest developer and publisher of international standards. Aggredyne’s ISO 13485 certificate was awarded by National Quality Assurance (NQA).

"For any medical device manufacturer, but especially for an early-stage company, ISO 13485 certification represents a significant growth milestone," said CEO Edward R. Teitel, M.D. "This designation, along with our previously earned CE mark, recognizes Aggredyne’s commitment to provide our customers with outstanding, high quality products and puts us on a path to increase international sales.”

Aggredyne recently doubled the size of its facility as it prepares for it next growth phase and expansion of its product line. “The larger facility will enable us to meet our growing demand as we advance to our next generation device,” said Andrew Yee, Aggredyne’s vice president of operations and manufacturing.

For more information: www.aggredyne.com

Related Content

News | Pharmaceuticals

May 24, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

Home May 24, 2022
Home
News | Pharmaceuticals

May 24, 2022 — The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has ...

Home May 24, 2022
Home
News | Pharmaceuticals

May 17, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

Home May 17, 2022
Home
News | Pharmaceuticals

May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) ...

Home May 13, 2022
Home
News | Pharmaceuticals

April 29, 2022 — Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Camzyos ...

Home April 29, 2022
Home
News | Pharmaceuticals
March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions ...
Home March 31, 2022
Home
News | Pharmaceuticals
March 22, 2022 – Fresenius Kabi, a global health care company that specializes in medicines and technologies for ...
Home March 22, 2022
Home
News | Pharmaceuticals

January 5, 2022 — The Feinstein Institutes for Medical Research, the science arm of Northwell Health, recently received ...

Home January 05, 2022
Home
News | Pharmaceuticals

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has cleared Novartis' inclisiran (Leqvio), the first small ...

Home January 04, 2022
Home
News | Pharmaceuticals

December 16, 2021 – Spanish pharmaceutical company Ferrer and the Spanish National Center for Cardiovascular Research ...

Home December 16, 2021
Home
Subscribe Now